Analyst consensus rating
Beta Bionics Analyst Rating: Buy
BBNX is rated Buy by 11 analysts with a $20.31 target. As of 2026-08-26.
Direct answer
Beta Bionics's consensus rating is Buy.
11 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $20.31.
Forecast evidence checked August 26, 2026.
Get free Beta Bionics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $19.34
- Average price target
- $20.31
- High price target
- $30.40
- Low price target
- $14.00
- Low target gap
- -27.6%
- Target upside
- +5%
- High target gap
- +57.2%
- Target range width
- 84.8%
- Consensus rating
- Buy
- Analysts
- 11
- Evidence date
- August 26, 2026
- Valid through
- September 2, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Beta Bionics?
Beta Bionics has a verified Buy consensus. The same dataset has an average price target of $20.31.
How far are Beta Bionics's low and high targets from the recorded price?
The low target implies -27.6%, while the high target implies +57.2%.
How many analysts are included in Beta Bionics's consensus?
The verified consensus includes 11 analysts.
How is Beta Bionics's target upside or downside calculated?
The average target of $20.31 is divided by the recorded price of $19.34, then one is subtracted to produce +5%. This does not guarantee a future return.
When was Beta Bionics's analyst forecast verified?
The data was verified on 2026-08-26. The dataset is valid through 2026-09-02.